FDA Brief

Warning letters Drugs

FDA warning letter to

NuScience Peptides LLC

High riskIssued Aug 24Posted Sep 1Center for Drug Evaluation and Research (CDER)

FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.

What happened

FDA reviewed the company's website, nusciencepeptides.com, in July 2026 and found nine products marketed with claims to treat or affect conditions such as obesity, type 2 diabetes and sexual function. FDA said the products are drugs and new drugs with no approved application, and that selling bacteriostatic water alongside them and a "peptide calculator" shows the water is meant for making injectable drugs for people.

What FDA found

  1. The website claims these peptides treat or affect the body, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The products are not generally recognized as safe and effective and have no FDA-approved application, so they are unapproved new drugs.

    Sections 201(p) and 505(a) of the FD&C Act, 21 U.S.C. 321(p) and 355(a)
  3. Shipping these unapproved new drugs across state lines breaks the law.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. Bacteriostatic water sold together with the peptides and a peptide calculator is itself a drug intended for injection.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  5. Labels saying "for laboratory, research, and analytical use" and "not intended for human use" do not override the website's drug claims.

    21 CFR 201.128

What FDA wants

FDA tells the company to find the root causes, correct the violations and prevent them from recurring, and to send a written response with the steps taken and supporting documents. The response is due within 15 business days of receiving the letter, sent to FDAAdvisory@fda.hhs.gov with reference number 733652 in the subject line.

Who should pay attention

  • clinics, med spas and resellers that buy research-labeled peptides
  • other online peptide sellers making similar weight-loss and hormone claims
  • consumers buying injectable peptides online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk